Literature DB >> 21545434

Mammary myofibrosarcoma: case report and literature review.

Matthew Stark1, Andrew Hoffmann, Zhenggang Xiong.   

Abstract

A case of myofibrosarcoma of breast is reported. A female patient aged 81 years presented with a mammary mass lesion. Histologically, the tumor consisted of neoplastic spindle cells arranged in fascicles and with variably cellularity and hyalinization. Immunohistochemical studies showed expression of vimentin, smooth-muscle actin, and Bcl-2, but not desmin, S-100, C-kit, or CD34. Proliferative index identified by Ki67 was approximately 30%. Electron microscopy revealed variable amount of rough endoplasmic reticulum, myofilaments, fibronexus junctions, and fibronectin fibrils. The histological, immunohistochemical, and ultrastructural features of this tumor were consistent with myofibrosarcoma. This case will be one of the very few cases of ultrastructurally confirmed mammary myofibrosarcoma reported in the literature and contributes to the recognition of this rare mammary malignant neoplasm. The literature on mammary myofibrosarcoma and its differential diagnosis is also reviewed.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21545434     DOI: 10.1111/j.1524-4741.2011.01070.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  3 in total

1.  Low-grade myofibroblastic sarcomas of the maxilla.

Authors:  Jin-Yu Qiu; Peng Liu; Ce Shi; Bing Han
Journal:  Oncol Lett       Date:  2014-12-11       Impact factor: 2.967

2.  Low-grade myofibroblastic sarcoma arising in fibroadenoma of the breast-A case report.

Authors:  Na-Hye Myong; Jun-Won Min
Journal:  Diagn Pathol       Date:  2016-03-25       Impact factor: 2.644

3.  PET-CT evaluation of the curative effect of crizotinib on malignant myofibroblastoma with rare mutation of ALK R401: a case report and literature review.

Authors:  Li Yang; Yufeng Wu; Hong Tang; Jiuzhou Zhao; Dongdong Zhao; Sen Yang; Qiming Wang
Journal:  Onco Targets Ther       Date:  2018-04-05       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.